MedWatch

Alligator is still hungry following major milestones

With a successful IPO and a lucrative partnership deal with Janssen under its belt, Sunstone-backed Alligator Biosciences is turning its focus on its proprietary pipeline and three promising candidate drugs.

Foto: Colourbox

The Swedish biotech company Alligator Biosciences has been on a positive trajectory in recent years. First, it struck a very lucrative deal with Janssen for lead asset ATOR-1013 that could amount to USD 700 million, and then followed an IPO late last year, which added additional funds to the coffers of the Lund-based company.

Those funds are now allowing the company to enter a new phase of its development.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier